Today, February 23rd, 2026, Gilead Sciences announced a definitive agreement to acquire Arcellx in a transaction valued at approximately $7.8 billion, providing Gilead with full ownership of anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR-T therapy for patients with relapsed or refractory multiple myeloma. Arcellx is a clinical-stage biotech company headquartered in Rockville, Maryland, founded in 2014. [Read more…]
Behind the Scenes at FUJIFILM Irvine Scientific (FISI) with Yutaka Yamaguchi (President)
FUJIFILM Irvine Scientific (FISI) is the world’s leading manufacturer of cell culture media, reagents, and medical devices that are used across the cell therapy, regenerative medicine, assisted reproductive technology, and industrial cell culture markets. The company adheres to ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA, and Tokyo, Japan.
While Irvine Scientific was founded in 1970, Fujifilm did not acquire the company until 2018, when it invested US$800 million to become a dominant force within the cell culture media and services market.
In this interview with Yutaka Yamaguchi, President of FUJIFILM Irvine Scientific (FISI), we explore the reasons for FUJIFILM’s acquisition of Irvine Scientific, the importance of the company’s dual manufacturing facilities, traits that differentiate FISI from its competitors, and trends within the Regenerative Medicine industry at large. [Read more…]
The Future of Stem Cell Therapy as Treatment for Autism
Treatment for autism is an increasingly important pursuit, as the Center for Disease Control and Prevention (CDC) estimates:
- 1 in 59 children has been identified with autism spectrum disorder (ASD) [Read article]
- Autism occurs in all racial, ethnic, and socioeconomic groups. [Read article]
- Studies in Asia, Europe, and North America have identified ASD to have a prevalence rate of between 1% and 2%. [Data table]
With autism spectrum disorder (ASD) affecting between 1-2% of the population, the condition is becoming of increasing importance and a treatment for autism is becoming a highly sought-after medical breakthrough.
The Dominance of Cell and Gene Therapy CDMOS in 2026
While there are many exciting market segments, the market for cell and gene therapy CDMO services is one of the most fascinating. A decade ago, there were only a handful of market competitors. Today, there are more than a hundred companies specializing in manufacturing and clinical trial support for cell and gene therapies (CGT)—and demand for their services continues to rise. [Read more…]
Longevity Medical Institute® Opens Federally Licensed Stem Cell and Regenerative Medicine Biotechnology Laboratory in Los Cabos
LOS CABOS, BAJA CALIFORNIA SUR, Mexico, March 3, 2026 — Longevity Medical Institute® today announced the opening of its federally licensed Stem Cell and Regenerative Medicine Biotechnology Laboratory, further expanding what is now one of the most comprehensive regenerative and advanced diagnostic medical campuses in Los Cabos. [Read more…]
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 339
- Next Page »